Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotechnology

This article was originally published in RAJ Devices

Executive Summary

Investigation into benefits, risks and adequacy of regulation

Investigation into benefits, risks and adequacy of regulation

The Royal Society and the Royal Academy of Engineering have been commissioned by the UK Government's Office of Science and Technology (OST) to investigate the potential benefits and possible problems associated with nanotechnology and nanoscience1.

The study began with a request to stakeholders to express their hopes and concerns about the new technology by 10 July 2003. It will go on to investigate the environmental, health and safety, ethical and societal implications and uncertainties that may arise from the use of the technology. It will also identify areas where additional regulation needs to be considered.

Nanotechnology, which already plays as important role in biomedicine and electronics, is the creation and utilisation of functional materials, devices and systems with novel functions and properties that are based either on geometrical size or on material-specific peculiarities of nanostructures.

References

1. UK Government Office of Science and Technology press release, 18 June 2003, www.ost.gov.uk

Latest Headlines
See All
UsernamePublicRestriction

Register

SC093066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel